---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-10-31T14:25:03.158496'
end_time: '2026-10-31T14:48:33.680756'
duration_seconds: 1410.52
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: RIN2 Syndrome
  mondo_id: MONDO:0013115
  category: Mendelian
  causal_genes: RIN2
  omim_id: OMIM:613075
  synonyms: MACS syndrome; RIN2 deficiency; macrocephaly-alopecia-cutis laxa-scoliosis
    syndrome; tall forehead-sparse hair-skin hyperextensibility-scoliosis syndrome
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderNotConfiguredError
  remedy: the provider is not configured
  retryable: false
- provider: openscientist
  succeeded: true
citation_count: 9
reference_validation:
  total_references: 9
  verified: 9
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 9
  on_topic: 7
  validator_version: 0.4.0
term_validation:
  total_terms: 36
  verified: 32
  not_found: 0
  obsolete: 2
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 31
  labels_matching: 12
  labels_mismatched: 18
  mislabelled_terms:
  - term_id: HP:0000256
    reported_labels:
    - Physical
    ontology_label: Macrocephaly
  - term_id: HP:0000280
    reported_labels:
    - Clinical sign
    ontology_label: Coarse facial features
  - term_id: HP:0000494
    reported_labels:
    - Physical
    ontology_label: Downslanted palpebral fissures
  - term_id: HP:0000508
    reported_labels:
    - Physical
    ontology_label: Ptosis
  - term_id: HP:0000202
    reported_labels:
    - thick lip
    ontology_label: Orofacial cleft
  - term_id: HP:0000212
    reported_labels:
    - Clinical sign
    ontology_label: Gingival overgrowth
  - term_id: HP:0000705
    reported_labels:
    - Physical
    ontology_label: Amelogenesis imperfecta
  - term_id: HP:0000973
    reported_labels:
    - Physical
    ontology_label: Cutis laxa
  - term_id: HP:0000974
    reported_labels:
    - Physical
    ontology_label: Hyperextensible skin
  - term_id: HP:0001382
    reported_labels:
    - Physical
    ontology_label: Joint hypermobility
  - term_id: HP:0002650
    reported_labels:
    - Clinical sign
    ontology_label: Scoliosis
  - term_id: HP:0002110
    reported_labels:
    - Clinical sign
    ontology_label: Bronchiectasis
  - term_id: HP:0000815
    reported_labels:
    - Lab/clinical
    ontology_label: Hypergonadotropic hypogonadism
  - term_id: HP:0000365
    reported_labels:
    - Clinical sign
    ontology_label: Hearing impairment
  - term_id: HP:0002352
    reported_labels:
    - Imaging
    ontology_label: Leukoencephalopathy
  - term_id: UBERON:0001708
    reported_labels:
    - gingiva
    ontology_label: jaw skeleton
  - term_id: GO:0005088
    reported_labels:
    - Ras GEF activity
    ontology_label: GO_0005088
  - term_id: GO:0017112
    reported_labels:
    - Rab GEF activity
    ontology_label: GO_0017112
  labels_variant: 1
  obsolete_terms:
  - term_id: GO:0005088
    ontology_label: GO_0005088
    replaced_by: GO:0005085
  - term_id: GO:0017112
    ontology_label: GO_0017112
    replaced_by: GO:0005085
  unresolvable_prefixes:
  - OMIM
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: RIN2_Syndrome-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: RIN2_Syndrome-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** RIN2 Syndrome
- **MONDO ID:** MONDO:0013115 (if available)
- **Causal gene(s):** RIN2
- **OMIM:** OMIM:613075
- **Synonyms:** MACS syndrome; RIN2 deficiency; macrocephaly-alopecia-cutis laxa-scoliosis syndrome; tall forehead-sparse hair-skin hyperextensibility-scoliosis syndrome
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **RIN2 Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# RIN2 Syndrome (MACS Syndrome): A Comprehensive Disease Characterization Report

**Disease:** RIN2 Syndrome / MACS Syndrome
**Causal gene:** **RIN2** (Ras and Rab Interactor 2; HGNC:18750; NCBI Gene 54453; UniProt Q8WYP3)
**MONDO ID:** MONDO:0013115 · **OMIM:** 613075 · **Chromosome:** 20p11.23

---

## Summary

RIN2 syndrome — also known as **MACS syndrome** (**M**acrocephaly, **A**lopecia, **C**utis laxa, **S**coliosis) — is an **ultra-rare autosomal recessive connective-tissue disorder** caused by **biallelic loss-of-function (truncating/frameshift) variants in the _RIN2_ gene** on chromosome 20p11.23. _RIN2_ encodes the **Ras and Rab Interactor 2** protein, a cytoplasmic **guanine-nucleotide-exchange factor (GEF) for RAB5B** and a **Ras effector** that regulates early endocytic vesicular trafficking. This report consolidates nine confirmed findings assembled across five investigation iterations, each grounded in the primary clinical and molecular literature.

The core mechanistic chain is now well supported: loss of functional RIN2 protein impairs Rab5-dependent endocytic and secretory trafficking (patient fibroblasts show dilated endoplasmic reticulum and abnormal Golgi cisternae), which reduces extracellular deposition of **fibulin-5** and **dermal microfibrils**, disrupting **elastic-fiber and collagen assembly** in connective tissue. Because fibulin-5 is essential for elastic-fiber formation (it bridges tropoelastin and fibrillin-1 microfibrils), its depletion produces the characteristic dermal and systemic connective-tissue phenotype: progressive facial coarsening, gingival (gum) hypertrophy, sparse scalp hair/alopecia, macrocephaly, soft redundant and/or hyperextensible skin, joint hypermobility, and scoliosis.

Clinically, RIN2 syndrome is diagnosed by recognizing the characteristic gestalt and confirming biallelic _RIN2_ variants by exome/genome or targeted sequencing. Only ~11–15 patients from ~6 consanguineous families had been reported through the early 2020s, making it one of the rarest known connective-tissue disorders. Management is **entirely supportive and multidisciplinary**; there is no disease-modifying drug, gene, or cell therapy, no clinical trial, and no published animal model. The course is chronic, lifelong, and slowly progressive but generally **non-lethal**, with survival into adulthood and generally preserved cognition.

---

## Key Findings

### Finding 1 — RIN2 syndrome is an autosomal recessive disorder caused by biallelic loss-of-function _RIN2_ variants

MACS syndrome was originally mapped to **chromosome 20p11.21–p11.23**, and a homozygous frameshift mutation in _RIN2_ was shown to segregate with the disease in a large consanguineous kindred, accompanied by decreased RIN2 expression ([PMID: 19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/)). Multiple independent families subsequently confirmed the gene, each harboring biallelic truncating/frameshift variants:

| Variant (cDNA / protein) | Consequence | Reference |
|---|---|---|
| Homozygous frameshift (founding kindred) | ↓ RIN2 expression | [PMID: 19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/) |
| c.1914_1915delGC (frameshift → PTC) | Nonsense-mediated decay (NMD) | [PMID: 20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/) |
| c.1878dupC p.Ile627Hisfs*7 | Truncation | [PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/) |
| c.1878_1879insC p.Ile627Hisfs*7 | Truncation | [PMID: 24449201](https://pubmed.ncbi.nlm.nih.gov/24449201/) |
| c.2251dup p.Leu751Profs*9 | Truncation | [PMID: 30769224](https://pubmed.ncbi.nlm.nih.gov/30769224/) |
| c.1938delT (frameshift) | Truncation | [PMID: 31521835](https://pubmed.ncbi.nlm.nih.gov/31521835/) |

> *"The disorder was mapped to chromosome 20p11.21-p11.23, and a homozygous frameshift mutation in RIN2 was found to segregate with the disease phenotype in a large consanguineous kindred."* — [PMID: 19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/)

> *"The c.1914_1915delGC mutation introduces a frameshift and creates a premature termination codon, leading to nonsense-mediated mRNA decay."* — [PMID: 20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/)

**Variant classification:** All reported pathogenic variants are **frameshift/truncating** (ACMG: pathogenic/likely pathogenic; PVS1 null-variant criterion applies given the LoF mechanism). No recurrent pathogenic missense variant is established. **Origin:** germline. **Functional consequence:** loss of function (through NMD for early truncations, or loss of the C-terminal Rab5-GEF/Ras-effector domains for later truncations).

### Finding 2 — RIN2 deficiency impairs Rab5-mediated endocytic trafficking, reducing dermal microfibrils and fibulin-5

RIN2 interacts with Rab5 and regulates early endocytic trafficking. RIN2 deficiency is associated with a **paucity of dermal microfibrils** and a **deficiency of fibulin-5** in the extracellular matrix, directly linking the molecular lesion to the connective-tissue phenotype ([PMID: 19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/)). Ultrastructural skin studies additionally revealed abnormal collagen-fibril morphology, and patient fibroblasts displayed a **dilated endoplasmic reticulum and abnormal Golgi apparatus with rarefied, dilated cisternae** — direct evidence of secretory-pathway dysfunction ([PMID: 20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/)).

The downstream importance of fibulin-5 is independently established: fibulin-5 is essential for elastic-fiber assembly, binding tropoelastin and fibrillin-1 microfibrils and facilitating deposition of elastin onto a microfibrillar scaffold. Its loss disorganizes dermal elastic fibers, and recessive fibulin-5 mutations cause cutis laxa through misfolding, decreased secretion, and reduced elastin/fibrillin-1 interaction ([PMID: 17035250](https://pubmed.ncbi.nlm.nih.gov/17035250/)).

> *"RIN2 deficiency was found to be associated with paucity of dermal microfibrils and deficiency of fibulin-5, which may underlie the abnormal skin phenotype displayed by the patients."* — [PMID: 19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/)

> *"fibroblasts exhibited a dilated endoplasmic reticulum and an abnormal Golgi apparatus with rarefied and dilated cisternae"* — [PMID: 20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/)

### Finding 3 — Characteristic progressive craniofacial and connective-tissue phenotype with expanding systemic features

Hallmark features include macrocephaly (normal-to-enlarged occipitofrontal circumference), **striking progressive facial coarsening**, downslanting palpebral fissures, puffy/droopy eyelids, full everted lips, **gingival (gum) hypertrophy**, irregular dentition, **sparse scalp hair/alopecia**, soft redundant and/or **hyperextensible skin**, **joint hypermobility**, and **scoliosis** ([PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/); [PMID: 30769224](https://pubmed.ncbi.nlm.nih.gov/30769224/); [PMID: 20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/)). Across families, the phenotype has expanded to include **bronchiectasis and hypergonadotropic hypogonadism** ([PMID: 24449201](https://pubmed.ncbi.nlm.nih.gov/24449201/)); **cervical vertebral fusion, mild hearing loss, and colonic fibrosis** ([PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/)); and **white-matter abnormalities/leukoencephalopathy** on brain MRI ([PMID: 30769224](https://pubmed.ncbi.nlm.nih.gov/30769224/)). The condition shows phenotypic overlap with Ehlers-Danlos syndrome (dermatosparaxis and kyphoscoliosis subtypes).

> *"Hallmark features of this condition include dysmorphic facial features with striking, progressive facial coarsening, sparse hair, normal to enlarged occipitofrontal circumference, soft redundant and/or hyperextensible skin, and scoliosis."* — [PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/)

> *"additional findings not previously described in MACS syndrome, including bronchiectasis and hypergonadotropic hypogonadism"* — [PMID: 24449201](https://pubmed.ncbi.nlm.nih.gov/24449201/)

**Phenotype table with suggested HPO terms:**

| Phenotype | Type | HPO term (suggested) | Frequency | Onset / Progression |
|---|---|---|---|---|
| Macrocephaly / enlarged OFC | Physical | HP:0000256 | Common | Congenital/early |
| Progressive facial coarsening | Clinical sign | HP:0000280 | Hallmark | Progressive |
| Downslanting palpebral fissures | Physical | HP:0000494 | Common | Congenital |
| Puffy/droopy eyelids (ptosis) | Physical | HP:0000508 | Common | Early |
| Full everted lips | Physical | HP:0000202 (thick lip) | Common | Early |
| Gingival hypertrophy | Clinical sign | HP:0000212 | Hallmark | Progressive |
| Irregular dentition | Physical | HP:0000705 | Common | Childhood |
| Sparse scalp hair / alopecia | Physical | HP:0002209 / HP:0001596 | Hallmark | Early |
| Cutis laxa / redundant skin | Physical | HP:0000973 | Hallmark | Congenital |
| Hyperextensible skin | Physical | HP:0000974 | Common | Congenital |
| Joint hypermobility | Physical | HP:0001382 | Common | Early |
| Scoliosis | Clinical sign | HP:0002650 | Hallmark | Progressive |
| Bronchiectasis | Clinical sign | HP:0002110 | Rare (expanded) | Variable |
| Hypergonadotropic hypogonadism | Lab/clinical | HP:0000815 | Rare (expanded) | Adolescence |
| Hearing loss (mild) | Clinical sign | HP:0000365 | Rare | Variable |
| Leukoencephalopathy / white-matter changes | Imaging | HP:0002352 | Rare (expanded) | Variable |

### Finding 4 — gnomAD constraint confirms _RIN2_ is LoF-tolerant in the heterozygous state, consistent with recessive inheritance

Gene-level constraint metrics from gnomAD (gene ENSG00000132669; chr20:19,757,606–20,002,457, GRCh38; canonical transcript ENST00000255006) show:

| Metric | Value | Interpretation |
|---|---|---|
| **pLI** | 0.003 | Far below the 0.9 haploinsufficiency threshold → **LoF-tolerant** |
| **LOEUF (oe_lof_upper)** | 0.61 | Moderate tolerance to LoF |
| **Observed/expected LoF** | 36/78 (oe = 0.46) | No strong depletion of LoF alleles |
| **Missense Z** | 0.91 | No significant missense constraint |

Heterozygous LoF alleles are present in the general population, which is fully consistent with **recessive inheritance** — a single intact allele suffices for health, and disease requires loss of both copies.

### Finding 5 — RIN2 protein architecture explains its role as a Rab5 GEF/Ras effector and why C-terminal truncations are pathogenic

UniProt **Q8WYP3** describes RIN2 as an **895-amino-acid cytoplasmic protein** with three key domains:

- **SH2 domain** (aa 97–190) — phosphotyrosine binding
- **VPS9 domain** (aa 618–757) — the catalytic **Rab5 guanine-nucleotide-exchange (GEF)** module
- **Ras-associating (RA) domain** (aa 787–878) — Ras effector interaction

UniProt annotates RIN2 as a *"Ras effector protein... May function as a guanine nucleotide exchange (GEF) of RAB5B, required for activating the RAB5 proteins by exchanging bound GDP for free GTP."* The protein is widely expressed (heart, kidney, lung, placenta), matching the systemic nature of the disease. Critically, the reported pathogenic truncations fall **at or around the VPS9 GEF domain and upstream of the RA domain** — p.Ile627Hisfs*7 ([PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/); [PMID: 24449201](https://pubmed.ncbi.nlm.nih.gov/24449201/)) and p.Leu751Profs*9 ([PMID: 30769224](https://pubmed.ncbi.nlm.nih.gov/30769224/)) — while earlier frameshifts trigger NMD ([PMID: 20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/); [PMID: 19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/)). Either way, the GEF/effector function is abolished.

> *"a ubiquitously expressed protein that interacts with Rab5 and is involved in the regulation of endocytic trafficking"* — [PMID: 19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/)

### Finding 6 — Ultra-rare disorder strongly linked to consanguinity and homozygous founder-like truncating alleles

Only **~11–15 patients from ~6 consanguineous families** (Algerian, Turkish, Italian, Iranian, Pakistani, and others) had been reported by 2020. [PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/) notes *"only nine patients from four independent families reported to date,"* and [PMID: 30769224](https://pubmed.ncbi.nlm.nih.gov/30769224/) describes the 11th patient. All reported families are **consanguineous** with homozygous truncating variants, and the same **p.Ile627Hisfs*7** allele recurred in independent families ([PMID: 24449201](https://pubmed.ncbi.nlm.nih.gov/24449201/); [PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/)). Because gnomAD shows the gene is LoF-tolerant, heterozygous carriers are healthy and asymptomatic. No formal carrier-frequency or population-prevalence estimate exists; **Orphanet classifies it as a rare genetic cutis-laxa/connective-tissue disorder with prevalence <1/1,000,000**.

> *"a rare autosomal recessive connective tissue disorder, with only nine patients from four independent families reported to date"* — [PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/)

> *"It is a rare condition, inherited in an autosomal recessive pattern."* — [PMID: 24449201](https://pubmed.ncbi.nlm.nih.gov/24449201/)

### Finding 7 — Gene is evolutionarily conserved, but no animal model recapitulating RIN2 syndrome exists

Ensembl orthology shows human _RIN2_ has one-to-one orthologs in **mouse** (_Rin2_, ENSMUSG00000001768, 91.4% aa identity), **rat** (ENSRNOG00000010131, 88.4%), **chicken** (68.9%), and **Xenopus** (65.8%), plus co-orthologs in **zebrafish** (~48–51%). However, the IMPC returned **zero phenotype annotations** for a mouse _Rin2_ knockout (numFound = 0), and **no published mouse/zebrafish/fly disease model** of RIN2 syndrome exists. Consequently, all mechanistic understanding derives from **human patient skin and fibroblast studies**: ultrastructural collagen/elastic-fiber abnormalities, dilated ER and abnormal Golgi, and reduced fibulin-5 and dermal microfibrils ([PMID: 20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/); [PMID: 19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/)).

> *"fibroblasts exhibited a dilated endoplasmic reticulum and an abnormal Golgi apparatus with rarefied and dilated cisternae"* — [PMID: 20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/)

### Finding 8 — Diagnosis rests on clinical recognition plus molecular confirmation, with a defined differential distinguished by normal glycosylation

Diagnosis is made by recognizing the characteristic **gestalt** (progressive facial coarsening, gingival hypertrophy, sparse hair, redundant/hyperextensible skin, scoliosis) and confirming **biallelic _RIN2_ variants** by exome/genome or targeted sequencing — all reported diagnoses used WES or gene sequencing ([PMID: 30769224](https://pubmed.ncbi.nlm.nih.gov/30769224/); [PMID: 31521835](https://pubmed.ncbi.nlm.nih.gov/31521835/)). Supportive investigations include **skin biopsy with electron microscopy** (paucity of dermal microfibrils, abnormal collagen morphology, dilated ER, abnormal Golgi, reduced fibulin-5 immunostaining; [PMID: 20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/); [PMID: 19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/)), **spine radiographs** for scoliosis, and **brain MRI** (may show leukoencephalopathy; [PMID: 30769224](https://pubmed.ncbi.nlm.nih.gov/30769224/)).

**Differential diagnosis:** RIN2 syndrome overlaps with **Ehlers-Danlos syndrome (dermatosparaxis and kyphoscoliosis subtypes)** and inherited cutis laxa syndromes ([PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/)). Unlike the **metabolic cutis laxa syndromes** (ATP6V0A2/ALG-related CDG, PYCR1, ALDH18A1/P5CS, Menkes/ATP7A, TALDO1, GORAB), RIN2 syndrome shows **normal glycosylation and metabolic screening**, which aids differentiation ([PMID: 21431621](https://pubmed.ncbi.nlm.nih.gov/21431621/)). The broad cutis-laxa differential, including MACS/RIN2, is catalogued in [PMID: 28409271](https://pubmed.ncbi.nlm.nih.gov/28409271/).

> *"Patients with RIN2 syndrome present phenotypic overlap with other conditions, including EDS (especially the dermatosparaxis and kyphoscoliosis subtypes)."* — [PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/)

> *"In metabolic cutis laxa syndromes the clinical and laboratory features might partially overlap, however there are some distinct, discriminative features."* — [PMID: 21431621](https://pubmed.ncbi.nlm.nih.gov/21431621/)

### Finding 9 — Management is entirely supportive; prognosis is chronic/progressive but non-lethal with preserved cognition

There is **no disease-modifying, pharmacological, gene, or cell therapy and no clinical trial** for RIN2 syndrome. Care is **symptomatic and multidisciplinary**, targeting each affected organ system:

| Organ system | Manifestation | Supportive management | NCIT term (suggested) |
|---|---|---|---|
| Orthopedic/spine | Progressive scoliosis | Bracing / corrective surgery | Scoliosis Surgery |
| Musculoskeletal | Joint hypermobility | Physiotherapy | Physical Therapy |
| Dental/periodontal | Gingival hypertrophy, irregular dentition | Dental/periodontal care | Dental Care |
| Dermatologic | Fragile/redundant skin | Skin protection | Supportive Care |
| Audiology | Hearing loss | Hearing aids/monitoring | Audiologic Evaluation |
| Respiratory | Bronchiectasis | Airway clearance, infection control | Respiratory Therapy |
| Endocrine | Hypergonadotropic hypogonadism | Hormone replacement | Hormone Replacement Therapy |
| Ophthalmology | Eyelid/periorbital features | Routine follow-up | Eye Care |

The course is **chronic, lifelong, and progressive** (facial coarsening and scoliosis worsen with age), but the oldest reported patient was an **adult** ([PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/)), indicating survival into adulthood. Intellect is generally normal/near-normal, and **no life-threatening large-vessel rupture** (as seen in vascular EDS) has been reported, although connective-tissue fragility is present.

> *"the oldest reported patient so far, who harbors the previously identified homozygous RIN2 mutation c.1878dupC"* — [PMID: 27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/)

> *"additional findings not previously described in MACS syndrome, including bronchiectasis and hypergonadotropic hypogonadism"* — [PMID: 24449201](https://pubmed.ncbi.nlm.nih.gov/24449201/)

---

## Section-by-Section Synthesis

### 1. Disease Information
RIN2 syndrome (MACS syndrome) is an ultra-rare autosomal recessive connective-tissue disorder. **Identifiers:** OMIM 613075; MONDO:0013115; Orphanet (rare cutis-laxa/connective-tissue disorder). **Synonyms:** MACS syndrome; RIN2 deficiency; macrocephaly-alopecia-cutis laxa-scoliosis syndrome; tall forehead–sparse hair–skin hyperextensibility–scoliosis syndrome. Information is derived from **aggregated case reports/series of individual consanguineous families** plus disease-level resources (OMIM/Orphanet), not from large EHR cohorts.

### 2. Etiology
**Primary cause:** genetic — biallelic loss-of-function _RIN2_ variants (Finding 1). **Genetic risk factor:** consanguinity (all reported families; Finding 6). There are **no established environmental, infectious, lifestyle, protective, or gene–environment modifiers** — the disorder is monogenic Mendelian with no reported modifier genes.

### 3. Phenotypes
See Finding 3 table (HPO terms and frequencies). Hallmark features are craniofacial/connective-tissue; expanded features are systemic. Quality-of-life impact is driven by progressive facial coarsening, scoliosis, dental/gingival disease, and skin fragility; no standardized QoL instruments have been applied.

### 4. Genetic/Molecular Information
Causal gene _RIN2_ (HGNC:18750; OMIM 610222 for the gene). All pathogenic variants reported are **frameshift/truncating**, germline, loss-of-function (Finding 1, 5). No modifier genes, epigenetic mechanisms, or chromosomal abnormalities are implicated. gnomAD constraint (Finding 4) supports recessive LoF.

### 5. Environmental Information
Not applicable — no environmental factors, lifestyle factors, or infectious agents are implicated in this monogenic disorder.

### 6. Mechanism / Pathophysiology
See the **Mechanistic Model** section below (ordered causal chain).

### 7. Anatomical Structures Affected
**Primary:** skin (UBERON:0002097), face/craniofacial structures (UBERON:0001456), gingiva (UBERON:0001708), vertebral column/spine (UBERON:0001130). **Secondary/expanded:** lung/bronchi (UBERON:0002048, bronchiectasis), gonads (hypogonadism), ear (hearing loss), brain white matter (leukoencephalopathy), colon (fibrosis). **Tissue level:** connective tissue (elastic fibers, collagen, microfibrils); **cell type:** dermal fibroblast (CL:0002620). **Subcellular:** endoplasmic reticulum (GO:0005783), Golgi apparatus (GO:0005794), early endosome (GO:0005769). **Lateralization:** bilateral/symmetric.

### 8. Temporal Development
**Onset:** congenital/early-childhood (macrocephaly, skin findings present early). **Pattern:** chronic, insidious, slowly progressive. **Progression:** facial coarsening and scoliosis worsen with age; no remission. **Duration:** lifelong. Childhood is the key window for orthopedic and dental intervention.

### 9. Inheritance and Population
**Inheritance:** autosomal recessive (Finding 1, 6). **Penetrance:** appears complete in biallelic individuals; expressivity is variable (expanded features vary by family). **Prevalence:** <1/1,000,000 (ultra-rare). **Consanguinity:** central risk factor; recurrent founder-like p.Ile627Hisfs*7 allele. **Carrier frequency:** not formally estimated; carriers asymptomatic. No genetic anticipation. **Sex ratio:** not established (both sexes affected). **Populations:** reported in Algerian, Turkish, Italian, Iranian, Pakistani and other consanguineous families.

### 10. Diagnostics
See Finding 8. Molecular confirmation (WES/WGS/targeted _RIN2_ sequencing) is definitive; skin biopsy/EM, spine radiographs, and brain MRI are supportive; metabolic/glycosylation screening is normal (distinguishes from metabolic cutis laxa).

### 11. Outcome/Prognosis
See Finding 9. Chronic, progressive connective-tissue morbidity (scoliosis, dental, skin, and expanded systemic complications) with **survival into adulthood** and generally preserved cognition; no reported fatal vascular rupture. No formal survival statistics exist given rarity.

### 12. Treatment
See Finding 9 table. Entirely **supportive/multidisciplinary** — orthopedic, physiotherapy, dental, dermatologic, audiologic, respiratory, endocrine, ophthalmologic. No pharmacotherapy, gene therapy, cell therapy, or targeted therapy; no clinical trials (no NCT identifiers).

### 13. Prevention
**Primary prevention:** genetic counseling for consanguineous families; carrier/cascade testing once the familial variant is known; prenatal/preimplantation genetic diagnosis available for at-risk pregnancies. **Secondary/tertiary:** early orthopedic and dental surveillance to prevent complications. No population screening or immunization is applicable.

### 14. Other Species / Natural Disease
_RIN2_ is conserved with clear mammalian orthologs (mouse _Rin2_ NCBI Gene 266971; Finding 7), but **no naturally occurring animal disease (OMIA) equivalent** has been reported. No zoonotic or veterinary relevance.

### 15. Model Organisms
**No published animal model** recapitulates RIN2 syndrome; IMPC has zero _Rin2_ knockout phenotype annotations (Finding 7). The principal experimental system is **patient-derived skin fibroblasts** (in vitro), which display the ER/Golgi and ECM defects. Mouse/zebrafish knockouts are feasible given conservation but have not been characterized for this disease.

---

## Mechanistic Model / Interpretation

### Ordered causal chain (initiating lesion → clinical manifestation)

1. **Biallelic truncating/frameshift mutation in _RIN2_** (germline, recessive) **leads to** either nonsense-mediated decay of the transcript (early truncations) or a protein lacking its C-terminal VPS9 GEF and RA domains (later truncations). *(Demonstrated — PMID 19631308, 20424861.)*
2. Loss of functional RIN2 **results in** absence of its **RAB5B guanine-nucleotide-exchange (GEF)** activity and loss of Ras-effector function. *(Inferred from UniProt domain function + observed truncation positions.)*
3. Failure to load RAB5 with GTP **impairs early endocytic and secretory vesicular trafficking**. *(Demonstrated at the cellular level — dilated ER and abnormal Golgi in patient fibroblasts, PMID 20424861.)*
4. Disrupted trafficking **reduces extracellular deposition of fibulin-5 and dermal microfibrils** in the extracellular matrix. *(Demonstrated — PMID 19631308.)*
5. Fibulin-5 deficiency **disrupts elastic-fiber assembly** (fibulin-5 normally bridges tropoelastin and fibrillin-1 microfibrils). *(Demonstrated for fibulin-5 biology — PMID 17035250.)*
6. Defective elastic-fiber and collagen matrix **leads to** the systemic connective-tissue phenotype, which **branches** into skin, craniofacial, skeletal, and other-system manifestations. *(Clinical associations observed; mechanistic link to expanded features inferred.)*

### ASCII schematic

```
 Biallelic LoF RIN2 (frameshift/truncation; recessive)
            │
            ▼
 NMD of transcript  OR  protein lacking VPS9-GEF + RA domains
            │
            ▼
 Loss of RAB5B GEF activity / Ras-effector function
            │
            ▼
 Impaired early endocytic + secretory trafficking
 (dilated ER, abnormal Golgi in fibroblasts)
            │
            ▼
 ↓ Fibulin-5 + ↓ dermal microfibrils in ECM
            │
            ▼
 Defective elastic-fiber / collagen assembly
            │
     ┌──────┼───────────┬──────────────┐
     ▼      ▼           ▼              ▼
   Skin   Craniofacial  Skeletal    Systemic (expanded)
 cutis   facial         scoliosis   bronchiectasis
 laxa    coarsening,    joint       hypogonadism
         gum hypertrophy hypermobility leukoencephalopathy
```

### Ontology term suggestions

- **Gene/protein:** HGNC:18750 (_RIN2_); UniProt Q8WYP3; NCBI Gene 54453
- **Biological processes (GO):** GO:0006897 (endocytosis); GO:0005088 (Ras GEF activity); GO:0017112 (Rab GEF activity); GO:0048251 (elastic fiber assembly)
- **Cellular components (GO):** GO:0005783 (endoplasmic reticulum); GO:0005794 (Golgi apparatus); GO:0005769 (early endosome)
- **Cell types (CL):** CL:0000057 (fibroblast); CL:0002620 (skin fibroblast)
- **Anatomy (UBERON):** UBERON:0002097 (skin); UBERON:0001456 (face); UBERON:0001708 (gingiva); UBERON:0001130 (vertebral column); UBERON:0002048 (lung)
- **Chemical entities (CHEBI):** CHEBI:17552 (GDP); CHEBI:15996 (GTP)
- **Disease:** MONDO:0013115; OMIM:613075

---

## Evidence Base

| PMID | Title (abbrev.) | Contribution | Evidence type |
|---|---|---|---|
| [19631308](https://pubmed.ncbi.nlm.nih.gov/19631308/) | RIN2 deficiency → MACS syndrome | Original gene mapping (20p11.21-23), recessive segregation, RIN2–Rab5 link, fibulin-5/microfibril deficiency | Human clinical + molecular |
| [20424861](https://pubmed.ncbi.nlm.nih.gov/20424861/) | RIN2 syndrome, new AR connective-tissue disorder | NMD mechanism (c.1914_1915delGC); fibroblast ER/Golgi ultrastructure | Human clinical + in vitro |
| [27277385](https://pubmed.ncbi.nlm.nih.gov/27277385/) | RIN2 syndrome: expanding the phenotype | Hallmark feature list; EDS differential; oldest adult patient; recurrent p.Ile627Hisfs*7 | Human clinical |
| [24449201](https://pubmed.ncbi.nlm.nih.gov/24449201/) | Novel features in two siblings (MACS) | Bronchiectasis + hypergonadotropic hypogonadism; AR inheritance | Human clinical |
| [30769224](https://pubmed.ncbi.nlm.nih.gov/30769224/) | Leukoencephalopathy in RIN2 syndrome | 11th patient; novel c.2251dup p.Leu751Profs*9; white-matter MRI changes | Human clinical |
| [31521835](https://pubmed.ncbi.nlm.nih.gov/31521835/) | RIN2 + BBS7 coincidental syndrome | Novel c.1938delT; WES strategy in consanguineous family | Human clinical |
| [17035250](https://pubmed.ncbi.nlm.nih.gov/17035250/) | Fibulin-5 mutations in recessive cutis laxa | Mechanism of fibulin-5 in elastic-fiber assembly (supports downstream step) | In vitro + human |
| [21431621](https://pubmed.ncbi.nlm.nih.gov/21431621/) | Metabolic cutis laxa syndromes | Differential diagnosis via glycosylation/metabolic screening | Review |
| [28409271](https://pubmed.ncbi.nlm.nih.gov/28409271/) | Cutis laxa with Leigh-like (ECHS1) | Catalogs cutis-laxa differential incl. MACS/RIN2 | Human clinical + review |

**Supporting vs. challenging:** All nine papers are mutually supporting; none challenges the core model. The fibulin-5 paper ([PMID: 17035250](https://pubmed.ncbi.nlm.nih.gov/17035250/)) supplies the mechanistic basis for the *downstream* elastic-fiber defect but concerns a different gene (FBLN5), so it is corroborative by analogy rather than direct proof of the RIN2 → fibulin-5 step. The gnomAD and UniProt data (Findings 4–5) are computational/database evidence that reinforce the recessive LoF model.

---

## Limitations and Knowledge Gaps

1. **Extreme rarity:** With only ~11–15 reported patients from ~6 consanguineous families, all phenotype frequencies, prognosis estimates, and genotype–phenotype correlations rest on small case series and may be biased toward severe, ascertained cases.
2. **No animal model:** Despite strong ortholog conservation (mouse _Rin2_ 91.4% identity), there is no published mouse/zebrafish/fly model and the IMPC has zero _Rin2_ knockout phenotype annotations. The causal chain between RIN2 loss and fibulin-5 depletion is therefore inferred from patient fibroblasts, not demonstrated in a controlled genetic model.
3. **Mechanistic gaps:** The precise step linking impaired Rab5 trafficking to reduced *fibulin-5 secretion* (vs. reduced synthesis or ECM retention) is not experimentally dissected. Whether the Ras-effector (RA-domain) function contributes independently of the Rab5-GEF function is unknown.
4. **Expanded-phenotype mechanisms:** The mechanistic basis for bronchiectasis, hypergonadotropic hypogonadism, and leukoencephalopathy is unexplained — these may reflect broad trafficking dysfunction in multiple tissues but lack direct evidence.
5. **Epidemiology undefined:** No carrier frequency, incidence, or formally measured prevalence exists; the <1/1,000,000 Orphanet estimate is a classification, not a measured value.
6. **No missense/structural-variant data:** All reported variants are truncating; the pathogenicity of potential missense or structural _RIN2_ variants is untested, leaving VUS interpretation uncertain.
7. **No natural-history or QoL data:** There are no longitudinal cohorts, standardized QoL instruments (EQ-5D/SF-36), or registry data for RIN2 syndrome.

---

## Proposed Follow-up Experiments / Actions

1. **Generate a genetic animal model.** Create a mouse _Rin2_ knockout or patient-mimicking frameshift knock-in (and/or zebrafish _rin2_ CRISPR line) and phenotype skin elastic fibers, craniofacial development, and spine — converting the currently *inferred* RIN2 → fibulin-5 → elastic-fiber chain into *demonstrated* causality.
2. **Mechanistic rescue in patient fibroblasts.** Test whether wild-type RIN2 re-expression restores Rab5-GTP loading, normalizes ER/Golgi ultrastructure, and rescues fibulin-5 secretion; use GEF-dead vs. RA-domain-mutant constructs to separate the two functions.
3. **Secretion vs. synthesis assay.** Use pulse-chase immunoprecipitation (as in the fibulin-5 cutis-laxa work) to determine whether fibulin-5 is under-synthesized, mis-secreted, or mis-deposited in RIN2-deficient cells.
4. **Multi-omics on patient tissue.** Apply transcriptomics/proteomics to patient fibroblasts (deposit in GEO/PRIDE) to map the full trafficking-defect signature and identify biomarkers.
5. **International registry + natural-history study.** Aggregate all known families via GeneMatcher/Orphanet to refine phenotype frequencies, define progression rates, and collect standardized QoL data.
6. **Structural modeling.** Use AlphaFold/experimental structures of the RIN2 VPS9–RA module with RAB5B to model how specific truncations ablate GEF activity and to assess future missense variants.
7. **Carrier-frequency estimation.** Mine gnomAD and population databases for _RIN2_ LoF alleles to produce a first quantitative carrier-frequency and expected-prevalence estimate, informing genetic counseling in consanguineous populations.

---

## Conclusion

RIN2 syndrome (MACS syndrome; OMIM 613075, MONDO:0013115) is an ultra-rare autosomal recessive connective-tissue disorder caused by **biallelic loss-of-function variants in _RIN2_** on chromosome 20p11.23. The encoded Ras and Rab Interactor 2 protein is a RAB5B guanine-nucleotide-exchange factor and Ras effector; its loss impairs Rab5-dependent endocytic/secretory trafficking, depletes fibulin-5 and dermal microfibrils, and disrupts elastic-fiber and collagen assembly, producing the progressive facial coarsening, gingival hypertrophy, sparse hair, macrocephaly, cutis laxa, joint hypermobility, and scoliosis that define the phenotype. Diagnosis requires molecular confirmation of biallelic _RIN2_ variants; management is purely supportive and multidisciplinary; and the course is chronic, progressive, but generally non-lethal with preserved cognition. The chief gaps are the absence of any animal model and the small number of reported patients, which limit mechanistic validation and epidemiologic precision.


## Artifacts

- [OpenScientist final report](RIN2_Syndrome-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](RIN2_Syndrome-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.4.0.

| Outcome | Count |
| --- | --- |
| References checked | 9 |
| Resolved | 9 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 9 |
| On topic | 7 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 36 |
| Resolved | 32 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 2 |
| Unverifiable | 2 |
| Terms whose name was checked | 31 |
| Terms named correctly | 12 |
| Terms named as a **different** term | 18 |
| Terms whose name is worth a second look | 1 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `HP:0000256` (1 mention) - the report calls it "Physical"; HP calls it **Macrocephaly**
- `HP:0000280` (1 mention) - the report calls it "Clinical sign"; HP calls it **Coarse facial features**
- `HP:0000494` (1 mention) - the report calls it "Physical"; HP calls it **Downslanted palpebral fissures**
- `HP:0000508` (1 mention) - the report calls it "Physical"; HP calls it **Ptosis**
- `HP:0000202` (1 mention) - the report calls it "thick lip"; HP calls it **Orofacial cleft**
- `HP:0000212` (1 mention) - the report calls it "Clinical sign"; HP calls it **Gingival overgrowth**
- `HP:0000705` (1 mention) - the report calls it "Physical"; HP calls it **Amelogenesis imperfecta**
- `HP:0000973` (1 mention) - the report calls it "Physical"; HP calls it **Cutis laxa**
- `HP:0000974` (1 mention) - the report calls it "Physical"; HP calls it **Hyperextensible skin**
- `HP:0001382` (1 mention) - the report calls it "Physical"; HP calls it **Joint hypermobility**
- `HP:0002650` (1 mention) - the report calls it "Clinical sign"; HP calls it **Scoliosis**
- `HP:0002110` (1 mention) - the report calls it "Clinical sign"; HP calls it **Bronchiectasis**
- `HP:0000815` (1 mention) - the report calls it "Lab/clinical"; HP calls it **Hypergonadotropic hypogonadism**
- `HP:0000365` (1 mention) - the report calls it "Clinical sign"; HP calls it **Hearing impairment**
- `HP:0002352` (1 mention) - the report calls it "Imaging"; HP calls it **Leukoencephalopathy**
- `UBERON:0001708` (2 mentions) - the report calls it "gingiva"; UBERON calls it **jaw skeleton**
- `GO:0005088` (1 mention) - the report calls it "Ras GEF activity"; GO calls it **GO_0005088**
- `GO:0017112` (1 mention) - the report calls it "Rab GEF activity"; GO calls it **GO_0017112**

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `GO:0005088` (GO_0005088) (1 mention) - replaced by `GO:0005085`
- `GO:0017112` (GO_0017112) (1 mention) - replaced by `GO:0005085`

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `UBERON:0002097` (2 mentions) - the report calls it "skin"; UBERON calls it **skin of body**, and lists "skin" among its other names

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `OMIM`.